Terms: = Leukemia AND FOXP1, MGC12942, 27086, ENSG00000114861, hFKH1B, MGC99551, FLJ23741, QRF1, 12CC4, HSPC215, MGC88572
42 results:
1. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract] [Full Text] [Related]
2. foxp1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells.
Levavasseur F; Oussous S; Zubaidan T; Kosmider O; Pendino F; Rombaut D; Bouscary D; Fontenay M; Lauret E; Dusanter-Fourt I
Blood Adv; 2023 Jul; 7(13):3265-3275. PubMed ID: 36930820
[TBL] [Abstract] [Full Text] [Related]
3. De novo damaging variants associated with congenital heart diseases contribute to the connectome.
Ji W; Ferdman D; Copel J; Scheinost D; Shabanova V; Brueckner M; Khokha MK; Ment LR
Sci Rep; 2020 Apr; 10(1):7046. PubMed ID: 32341405
[TBL] [Abstract] [Full Text] [Related]
4. MN1, foxp1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract] [Full Text] [Related]
5. The life and death of the germinal center.
Gars E; Butzmann A; Ohgami R; Balakrishna JP; O'Malley DP
Ann Diagn Pathol; 2020 Feb; 44():151421. PubMed ID: 31751845
[TBL] [Abstract] [Full Text] [Related]
6. The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies.
Filip D; Mraz M
Leuk Lymphoma; 2020 Mar; 61(3):510-524. PubMed ID: 31631728
[TBL] [Abstract] [Full Text] [Related]
7. BCR-ABL1-like B-Lymphoblastic leukemia/Lymphoma with foxp1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
Yenamandra AK; Kaviany S; Borinstein SC; Friedman DL; Kovach AE
Lab Med; 2019 Oct; 50(4):401-405. PubMed ID: 30938769
[TBL] [Abstract] [Full Text] [Related]
8. MicroRNA miR-34a downregulates foxp1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
Cerna K; Oppelt J; Chochola V; Musilova K; Seda V; Pavlasova G; Radova L; Arigoni M; Calogero RA; Benes V; Trbusek M; Brychtova Y; Doubek M; Mayer J; Pospisilova S; Mraz M
Leukemia; 2019 Feb; 33(2):403-414. PubMed ID: 30111844
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
[TBL] [Abstract] [Full Text] [Related]
10. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Choidas A; Habenberger P; Mahboubi B; Kim B; Bergmann A; Scholtysik R; Brauser M; Lollies A; Siebert R; Zenz T; Dührsen U; Küppers R; Dürig J
Blood Cancer J; 2018 Jan; 8(1):11. PubMed ID: 29352181
[TBL] [Abstract] [Full Text] [Related]
11. PUMILIO/foxp1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells.
Naudin C; Hattabi A; Michelet F; Miri-Nezhad A; Benyoucef A; Pflumio F; Guillonneau F; Fichelson S; Vigon I; Dusanter-Fourt I; Lauret E
Blood; 2017 May; 129(18):2493-2506. PubMed ID: 28232582
[TBL] [Abstract] [Full Text] [Related]
12. The small foxp1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length foxp1 exert similar oncogenic and transcriptional activity in human B cells.
van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
[TBL] [Abstract] [Full Text] [Related]
13. Direct interaction of Ikaros and foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.
Bond J; Domaschenz R; Roman-Trufero M; Sabbattini P; Ferreiros-Vidal I; Gerrard G; Asnafi V; Macintyre E; Merkenschlager M; Dillon N
Oncotarget; 2016 Oct; 7(40):65923-65936. PubMed ID: 27588474
[TBL] [Abstract] [Full Text] [Related]
14. Mapping epigenetic changes to the host cell genome induced by Burkholderia pseudomallei reveals pathogen-specific and pathogen-generic signatures of infection.
Cizmeci D; Dempster EL; Champion OL; Wagley S; Akman OE; Prior JL; Soyer OS; Mill J; Titball RW
Sci Rep; 2016 Aug; 6():30861. PubMed ID: 27484700
[TBL] [Abstract] [Full Text] [Related]
15. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
Saleh LM; Wang W; Herman SE; Saba NS; Anastas V; Barber E; Corrigan-Cummins M; Farooqui M; Sun C; Sarasua SM; Zhao Z; Abousamra NK; Elbaz O; Abdelghaffar HA; Wiestner A; Calvo KR
Leukemia; 2017 Feb; 31(2):340-349. PubMed ID: 27431016
[TBL] [Abstract] [Full Text] [Related]
16. foxp1 Expression in Normal and Neoplastic Erythroid and Myeloid Cells.
Lovrić E; Pavlov KH; Korać P; Dominis M
Coll Antropol; 2015 Sep; 39(3):755-9. PubMed ID: 26898077
[TBL] [Abstract] [Full Text] [Related]
17. foxp1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract] [Full Text] [Related]
18. A novel foxp1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia.
Sugimoto Y; Sada A; Shimokariya Y; Monma F; Ohishi K; Masuya M; Nobori T; Matsui T; Katayama N
Cancer Genet; 2015 Oct; 208(10):508-12. PubMed ID: 26319757
[TBL] [Abstract] [Full Text] [Related]
19. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
Deng L; Xu-Monette ZY; Loghavi S; Manyam GC; Xia Y; Visco C; Huh J; Zhang L; Zhai Q; Wang Y; Qiu L; Dybkær K; Chiu A; Perry AM; Zhang S; Tzankov A; Rao H; Abramson J; Sohani AR; Xu M; Hsi ED; Zhu J; Ponzoni M; Wang S; Li L; Zhang M; Ferreri AJ; Parsons BM; Li Y; Piris MA; Medeiros LJ; Young KH
Leukemia; 2016 Feb; 30(2):361-72. PubMed ID: 26308769
[TBL] [Abstract] [Full Text] [Related]
20. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract] [Full Text] [Related]
[Next]
